<DOC>
	<DOCNO>NCT00735267</DOCNO>
	<brief_summary>This study assess long-term safety tolerability 350 600 mg/day PD 0332334 administer split dose ( twice daily ) subject Generalized Anxiety Disorder .</brief_summary>
	<brief_title>A 52-Week Open-Label Safety Study PD 0332334 Subjects With Generalized Anxiety Disorder ( GAD )</brief_title>
	<detailed_description>Termination reason : On February 23rd 2009 , decision terminate development PD 0332334 communicate investigator study . The decision terminate study base safety concern .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Subjects must complete phase one four precede doubleblind GAD study . Female must continue use adequate birth control method negative serum pregnancy test within 14 day prior start open label treatment . Subjects experience serious adverse event precede doubleblind efficacy study judge related study medication investigator sponsor 's medical monitor . Individuals ongoing , unresolved , clinically significant medical problem , judgment investigator sponsor 's medical monitor , would make unsafe subject participate study . Serious suicidal risk per clinical investigator 's judgement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Generalized Anxiety Disorder</keyword>
</DOC>